This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

More proximal or extensive disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • for more proximal or extensive onychomycosis topical treatments are unlikely to be effective and systemic treatment should be considered

  • the systemic treatment of choice is Terbinafine 250mg daily. This should be continued for between 6 weeks and 3 months in fingernail infection, or for 3 to 6 months in toenail onychomycosis (1). Further cultures might be taken at 3 months to assess the necessity for prolonged treatment. In cases of toenail dystrophy a nail paint may also be added in. The success of treatment is of cure in 80-95% of cases. Terbinafine interacts with relatively few other drugs and is generally well tolerated

  • alternative systemic treatments for dermatophyte onychomycosis include
    • Itraconazole as pulsed therapy - 200mg twice daily for 1 week a month for 2 months in fingernail and for 3 months in toenail infections
    • Griseofulvin 10mg/kg/daily for 6-9 months in fingernail infection or 15-18 months for toenails (no longer considered as a treatment option for dermatophyte infections)

 

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.